Alnylam shares take a hit amid sluggish sales of first drug

Shares of Alnylam Pharmaceuticals fell Wednesday after the Cambridge biotech reported a slow uptake of its first FDA-approved drug, an expensive, first-of-its-kind treatment for a rare disease that is difficult to diagnose. In August, Alnylam (Nasdaq: ALNY) became the first company to receive FDA approval for a drug using a new gene-silencing technology called RNA interference, or RNAi. The drug, Onpattro, treats a rare disease called hereditary ATTR amyloidosis that is hard to diagnose, which poses…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news